TransMedics Group Inc. (TMDX)
TransMedics: Upcoming Trials Are Critical
Concerns about seasonal weakness have dragged TransMedics' share price lower in recent weeks. While TransMedics' growth is moderating, there remains a sizeable growth opportunity within just the U.S. liver market. TMDX's next-gen heart and lung programs, kidney device development, and international expansion could also drive significant growth longer term.
TransMedics: Just Like The CEO, I'm Buying
TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company's unique OCS platform, integrated logistics, and service model create a strong moat, with next-gen products and international expansion as major growth catalysts. Financials are robust: Q2 2025 revenue grew 37.7% YoY, margins improved, and guidance was raised.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3
TransMedics delivered another strong beat-and-raise quarter, but Q3 faces a likely seasonal slowdown that could disappoint optimistic investors. The long-term thesis remains robust: best-in-class preservation, logistics, and expansion into new organs and geographies support significant growth potential. Despite recent CEO insider buying, the purchase is negligible relative to his holdings, and appears more symbolic than a signal of confidence.
Here's Why TransMedics (TMDX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why TransMedics (TMDX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX broke out above the 50-day moving average, suggesting a short-term bullish trend.
Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why TransMedics (TMDX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
TransMedics: Continued Strength Suggests Further Upside
TransMedics delivered strong Q2 results, with revenue growth remaining robust and margins improving sharply. While there are concerns around the regulatory environment, competition, and seasonality, TransMedics' next-gen heart and lung programs are near-term growth catalysts. I see further upside, but meaningful gains may not materialize until 2026, when the heart and lung opportunity becomes more clear.
TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Dorothy Morgan - Gilmartin Group LLC K. Gong - JPMorgan Chase & Co, Research Division Christian Pasquale - Nephron Research Joshua Jennings - TD Cowen, Research Division Samantha Munoz - Piper Sandler & Co., Research Division Zachary Day - Canaccord Genuity Xuesong Wang - Morgan Stanley Suraj Kalia - Oppenheimer & Co. Inc., Research Division David Rescott - Robert W.
